The earnings call reflected a mixed sentiment with several positive signs of growth in the clinical market and successful adoption of new platforms. However, challenges remain in the research market due to funding constraints and ongoing issues in China, resulting in a balanced perspective of the company's performance.

Company Guidance

During the second quarter of fiscal year 2025, Illumina reported revenue at the high end of its guidance range, approximately $1.06 billion, despite a year-over-year decline. The company achieved a non-GAAP operating margin of 23.8% and a non-GAAP EPS of $1.19, surpassing expectations. Greater than 50 new placements of the NovaSeq X platform contributed to high-throughput consumable sales growth, particularly among NovaSeq X users. Clinical markets accounted for about 60% of total sequencing consumables, with oncology and genetic disease testing showing strong demand. The company experienced a decline in the research segment, particularly in the U.S., due to NIH funding uncertainties. Illumina raised its full-year guidance, forecasting total company revenue growth in constant currency to decline between 0.5% and 2.5%, with an increased operating margin target of 22% to 22.5%, and non-GAAP EPS between $4.45 and $4.55.

Revenue and Profitability

Despite a year-over-year decline, Illumina delivered revenue at the high end of guidance at $1.06 billion, with a non-GAAP operating margin of 23.8% and a non-GAAP EPS of $1.19, reflecting strong execution and profitability above expectations.

Clinical Market Strength

Clinical markets now account for roughly 60% of total sequencing consumables, with strong demand in oncology, genomic profiling, and reproductive health. Clinical growth is driven by expanding genome programs and broader adoption of whole genome sequencing.

NovaSeq X Platform Adoption

Ongoing adoption of the NovaSeq X platform with greater than 50 placements, and increased high-throughput consumable sales, particularly among NovaSeq X users.

Innovation and Multiomics Strategy

Progress in the multiomics strategy with updates to the innovation roadmap and the acquisition of SomaLogic, enhancing the proteomics capabilities and integrating with sequencing platforms.

Increased Guidance for 2025

Raised guidance for total company revenue growth, non-GAAP operating margin, and non-GAAP EPS, reflecting strong execution and operating discipline.

Illumina (ILMN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ILMN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	1.17 / -	1.14	―	―	―
Jul 31, 2025	2025 (Q2)	1.01 / 1.19	0.36	230.56% (+0.83)
May 08, 2025	2025 (Q1)	0.94 / 0.97	0.087	1014.94% (+0.88)
Feb 06, 2025	2024 (Q4)	0.91 / 0.95	0.136	598.53% (+0.81)
Nov 04, 2024	2024 (Q3)	0.88 / 1.14	0.321	255.14% (+0.82)
Aug 06, 2024	2024 (Q2)	0.11 / 0.36	0.311	15.76% (+0.05)
May 02, 2024	2024 (Q1)	0.04 / 0.09	0.078	11.54% (<+0.01)
Feb 08, 2024	2023 (Q4)	0.02 / 0.14	0.136	0.00% (0.00)
Nov 09, 2023	2023 (Q3)	0.14 / 0.32	0.33	-2.73% (>-0.01)
Aug 09, 2023	2023 (Q2)	0.02 / 0.31	0.554	-43.86% (-0.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ILMN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$102.71	$94.66	-7.84%
May 08, 2025	$79.58	$75.76	-4.80%
Feb 06, 2025	$122.80	$111.06	-9.56%
Nov 04, 2024	$153.49	$154.96	+0.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.